U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care* [Yahoo! Finance]
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
These Institutional Investors Are Raising Their Stakes in Johnson & Johnson Stock. Should You Do the Same? [Yahoo! Finance]
Johnson & Johnson (NYSE:JNJ) was given a new $197.00 price target on by analysts at Morgan Stanley.
Is J&J's 45.8% 2025 Surge Justified by Its Cash Flow and Earnings Outlook? [Yahoo! Finance]